JP2023527311A5 - - Google Patents

Info

Publication number
JP2023527311A5
JP2023527311A5 JP2022571187A JP2022571187A JP2023527311A5 JP 2023527311 A5 JP2023527311 A5 JP 2023527311A5 JP 2022571187 A JP2022571187 A JP 2022571187A JP 2022571187 A JP2022571187 A JP 2022571187A JP 2023527311 A5 JP2023527311 A5 JP 2023527311A5
Authority
JP
Japan
Prior art keywords
bispecific
individualized
cell
binding chain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022571187A
Other languages
English (en)
Japanese (ja)
Other versions
JP7753256B2 (ja
JP2023527311A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000340 external-priority patent/WO2021234453A1/en
Publication of JP2023527311A publication Critical patent/JP2023527311A/ja
Publication of JP2023527311A5 publication Critical patent/JP2023527311A5/ja
Application granted granted Critical
Publication of JP7753256B2 publication Critical patent/JP7753256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022571187A 2020-05-20 2021-05-19 二重特異性個別化アプタマー Active JP7753256B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063027629P 2020-05-20 2020-05-20
US63/027,629 2020-05-20
US202063121079P 2020-12-03 2020-12-03
US63/121,079 2020-12-03
PCT/IB2021/000340 WO2021234453A1 (en) 2020-05-20 2021-05-19 Bispecific personalized aptamers

Publications (3)

Publication Number Publication Date
JP2023527311A JP2023527311A (ja) 2023-06-28
JP2023527311A5 true JP2023527311A5 (cg-RX-API-DMAC7.html) 2024-05-28
JP7753256B2 JP7753256B2 (ja) 2025-10-14

Family

ID=76845262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571187A Active JP7753256B2 (ja) 2020-05-20 2021-05-19 二重特異性個別化アプタマー

Country Status (6)

Country Link
US (1) US20230193285A1 (cg-RX-API-DMAC7.html)
EP (1) EP4153750A1 (cg-RX-API-DMAC7.html)
JP (1) JP7753256B2 (cg-RX-API-DMAC7.html)
CN (1) CN116419763A (cg-RX-API-DMAC7.html)
IL (1) IL298347A (cg-RX-API-DMAC7.html)
WO (1) WO2021234453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146140B2 (en) 2020-12-03 2024-11-19 Aummune Ltd. T-lymphocyte binding aptamers
US20250215382A1 (en) * 2023-12-31 2025-07-03 Trenchant BioSystems, Inc. Functionally closed cell processing system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1620547B1 (en) * 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2010060030A1 (en) * 2008-11-24 2010-05-27 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
US11219635B2 (en) * 2016-02-19 2022-01-11 City Of Hope Bi-specific aptamer
AU2018214601A1 (en) * 2017-02-02 2019-08-15 Caris Science, Inc. Targeted oligonucleotides
CN107794267B (zh) * 2017-03-14 2021-03-26 湖南大学 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物
CN107483987B (zh) 2017-06-30 2020-02-07 武汉斗鱼网络科技有限公司 一种视频流地址的鉴权方法及装置
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
CN113423833B (zh) * 2018-09-28 2024-09-17 奥曼尼提纳米有限公司 用于选择功能性适体的方法和组合物

Similar Documents

Publication Publication Date Title
AU2022204601B2 (en) Methods for enhancing efficacy of therapeutic immune cells
US10662427B2 (en) Compositions and methods for inhibiting gene expression of LPA
RU2744194C2 (ru) Иммунотерапия рака
US8895242B2 (en) Single molecule nucleic acid nanoparticles
CN110914431B (zh) 经人工操纵的免疫细胞
JP4843177B2 (ja) 遺伝子の阻害剤またはサプレッサーおよびその遺伝子の発現産物に結合する分子を含有する混合物
CN113164507A (zh) 由多个寡核苷酸构成的通过与靶标的互补相互作用调控基因表达的多靶向核酸构建体
JP2024512608A5 (cg-RX-API-DMAC7.html)
IL299855A (en) Inhibitors of line1 and uses thereof
EP4362984A1 (en) Compositions and methods for treating cancers
JP7043114B2 (ja) 細胞を活性化させるための方法およびキット
EP3974531A1 (en) Asymmetric sirna inhibiting expression of pd-1
JP7753256B2 (ja) 二重特異性個別化アプタマー
WO2023034864A1 (en) Compositions and methods for treating cancers
JP2023553193A5 (cg-RX-API-DMAC7.html)
US11053503B2 (en) Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition
JP7837345B2 (ja) Tリンパ球結合アプタマー
CN118159299A (zh) 用于治疗癌症的组合物和方法
Chen et al. Synthetic immunity to break down the bottleneck of cancer immunotherapy
US20230285558A1 (en) Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
WO2025079599A1 (ja) サブセットレベルで細胞を標的化可能な担体およびその製造方法
WO2026076302A1 (en) Novel method to generate "metabolically-fit" til for cancer immunotherapy
CN117280033A (zh) T-淋巴细胞结合适体
HK40027138A (en) Artificially manipulated immune cell